Michał Falco1, Bartłomiej Masojć1, Marta Milchert-Leszczyńska1, Andrzej Kram2. 1. Radiation Oncology Department, West Pomeranian Oncology Center, Strzałowska 22, 71-730 Szczecin, Poland. 2. Pathology Department, West Pomeranian Oncology Center, Strzałowska 22, 71-730 Szczecin, Poland.
Abstract
BACKGROUND: Accelerated partial breast irradiation (APBI) is a promising method of adjuvant radiotherapy for select patients. Intraoperative radiotherapy (IORT) is a form of APBI, and appropriate patient selection is important. AIM: The aim of our study was to analyse the influence of our protocol on the frequency of WBRT after IORT and our protocol's correlation with the reported use of WBRT according to TARGIT guidelines. We also aimed to verify how changes in our protocol influenced the frequency of WBRT. MATERIAL AND METHODS: Between April 20, 2010 and May 10, 2017, we identified 207 patients irradiated with IORT for APBI. RESULTS: Ninety-one patients (44%) met the criteria for APBI only, while 116 (56%) should have been offered additional WBRT. Retrospective analysis showed that WBRT was applied statistically significantly less frequently compared with strict protocol indications: 99 patients (47.8%) received APBI only and 108 (51.2%) underwent adjuvant WBRT (p < 0.0001). Applying the TARGIT trial guidelines, 69 patients (33.4%) should have been offered WBRT (p < 0.0001), which is twice the number of patients treated with WBRT in our study. Changing the protocol to less restrictive criteria would have statistically significantly decreased the number of patients (95, 46%) offered WBRT (p < 0.0001). CONCLUSIONS: Following international guidelines, 46% of patients should receive WBRT after IORT, which is 1.5-2 times more than for the TARGIT criteria. In our analysis, a high percentage of patients (19%) did not receive WBRT after IORT despite the protocol recommendations. The chosen protocol strongly influences the frequency of adjuvant WBRT.
BACKGROUND: Accelerated partial breast irradiation (APBI) is a promising method of adjuvant radiotherapy for select patients. Intraoperative radiotherapy (IORT) is a form of APBI, and appropriate patient selection is important. AIM: The aim of our study was to analyse the influence of our protocol on the frequency of WBRT after IORT and our protocol's correlation with the reported use of WBRT according to TARGIT guidelines. We also aimed to verify how changes in our protocol influenced the frequency of WBRT. MATERIAL AND METHODS: Between April 20, 2010 and May 10, 2017, we identified 207 patients irradiated with IORT for APBI. RESULTS: Ninety-one patients (44%) met the criteria for APBI only, while 116 (56%) should have been offered additional WBRT. Retrospective analysis showed that WBRT was applied statistically significantly less frequently compared with strict protocol indications: 99 patients (47.8%) received APBI only and 108 (51.2%) underwent adjuvant WBRT (p < 0.0001). Applying the TARGIT trial guidelines, 69 patients (33.4%) should have been offered WBRT (p < 0.0001), which is twice the number of patients treated with WBRT in our study. Changing the protocol to less restrictive criteria would have statistically significantly decreased the number of patients (95, 46%) offered WBRT (p < 0.0001). CONCLUSIONS: Following international guidelines, 46% of patients should receive WBRT after IORT, which is 1.5-2 times more than for the TARGIT criteria. In our analysis, a high percentage of patients (19%) did not receive WBRT after IORT despite the protocol recommendations. The chosen protocol strongly influences the frequency of adjuvant WBRT.
Entities:
Keywords:
Accelerated partial breast irradiation; Breast cancer; Intraoperative radiotherapy; Whole breast irradiation
Authors: Ivo A Olivotto; Timothy J Whelan; Sameer Parpia; Do-Hoon Kim; Tanya Berrang; Pauline T Truong; Iwa Kong; Brandy Cochrane; Alan Nichol; Isabelle Roy; Isabelle Germain; Mohamed Akra; Melanie Reed; Anthony Fyles; Theresa Trotter; Francisco Perera; Wayne Beckham; Mark N Levine; Jim A Julian Journal: J Clin Oncol Date: 2013-07-08 Impact factor: 44.544
Authors: Csaba Polgár; Erik Van Limbergen; Richard Pötter; György Kovács; Alfredo Polo; Jaroslaw Lyczek; Guido Hildebrandt; Peter Niehoff; Jose Luis Guinot; Ferran Guedea; Bengt Johansson; Oliver J Ott; Tibor Major; Vratislav Strnad Journal: Radiother Oncol Date: 2010-02-22 Impact factor: 6.280
Authors: Barbara Belletti; Jayant S Vaidya; Sara D'Andrea; Frank Entschladen; Mario Roncadin; Francesca Lovat; Stefania Berton; Tiziana Perin; Ezio Candiani; Sonia Reccanello; Andrea Veronesi; Vincenzo Canzonieri; Mauro G Trovò; Kurt S Zaenker; Alfonso Colombatti; Gustavo Baldassarre; Samuele Massarut Journal: Clin Cancer Res Date: 2008-03-01 Impact factor: 12.531
Authors: Benjamin D Smith; Douglas W Arthur; Thomas A Buchholz; Bruce G Haffty; Carol A Hahn; Patricia H Hardenbergh; Thomas B Julian; Lawrence B Marks; Dorin A Todor; Frank A Vicini; Timothy J Whelan; Julia White; Jennifer Y Wo; Jay R Harris Journal: Int J Radiat Oncol Biol Phys Date: 2009-07-15 Impact factor: 7.038
Authors: Joanne S Haviland; J Roger Owen; John A Dewar; Rajiv K Agrawal; Jane Barrett; Peter J Barrett-Lee; H Jane Dobbs; Penelope Hopwood; Pat A Lawton; Brian J Magee; Judith Mills; Sandra Simmons; Mark A Sydenham; Karen Venables; Judith M Bliss; John R Yarnold Journal: Lancet Oncol Date: 2013-09-19 Impact factor: 41.316
Authors: S Darby; P McGale; C Correa; C Taylor; R Arriagada; M Clarke; D Cutter; C Davies; M Ewertz; J Godwin; R Gray; L Pierce; T Whelan; Y Wang; R Peto Journal: Lancet Date: 2011-10-19 Impact factor: 79.321
Authors: Jayant S Vaidya; Frederik Wenz; Max Bulsara; Jeffrey S Tobias; David J Joseph; Mohammed Keshtgar; Henrik L Flyger; Samuele Massarut; Michael Alvarado; Christobel Saunders; Wolfgang Eiermann; Marinos Metaxas; Elena Sperk; Marc Sütterlin; Douglas Brown; Laura Esserman; Mario Roncadin; Alastair Thompson; John A Dewar; Helle M R Holtveg; Steffi Pigorsch; Mary Falzon; Eleanor Harris; April Matthews; Chris Brew-Graves; Ingrid Potyka; Tammy Corica; Norman R Williams; Michael Baum Journal: Lancet Date: 2013-11-11 Impact factor: 79.321
Authors: Fantine Giap; Lillie O'steen; I-Chia Liu; Lisa E Spiguel; Christiana M Shaw; Christopher G Morris; Raymond B Mailhot Vega; Judith L Lightsey; Julie A Bradley; Nancy P Mendenhall; Paul G Okunieff; Natalie A Lockney Journal: Rep Pract Oncol Radiother Date: 2022-09-19